Although PD-1/PD-L1 blockade therapy is the first line of treatment for different cancer types, the combination with NKG2A mAb was also tested in the PD-1/PD-L1-responsive MC38 mouse colon tumor model. This evidence concerns the gene KLRC1 and cancer.